Antibody targeting DLL3, chimeric antigen receptor and application thereof
By developing high affinity and specificity targeting DLL3 antibodies and chimeric antigen receptors, the problem of insufficient affinity and specificity of existing antibodies has been solved, and more effective DLL3-targeted treatment has been achieved.
CN119708238AActive Publication Date: 2025-03-28THINKINGBIOMED TECHNOLOGY (BEIJING) CO LTD
11 Cites 0 Cited by
Patent Information
- Application Number
- CN202510221677.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-02-27
- Publication Date
- 2025-03-28
- Estimated Expiration
- 2045-02-27
AI Technical Summary
Technical Problem
The existing anti-human DLL3 antibodies lack affinity and specificity, resulting in off-target effects and adverse reactions.
Method used
Develop antibodies and chimeric antigen receptors targeting DLL3 with higher affinity and specificity, including specific heavy and light chain variable region amino acid sequences.
Benefits of technology
It improves the binding ability and target specificity of antibodies to DLL3, reduces off-target effects and adverse reactions, and enhances the killing effect on DLL3-high-expressing tumors such as small-cell lung cancer.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention relates to a DLL3-targeting antibody, a chimeric antigen receptor and application thereof. Specifically, the invention provides an antibody targeting DLL3 or an antigen binding fragment thereof, a chimeric antigen receptor (CAR) fusion protein containing an antigen binding domain targeting DLL3, and an engineered immune cell (such as a CAR-T cell) expressing the CAR fusion protein. The CAR-T cell disclosed by the invention has relatively high affinity and biological activity, and a relatively good anti-tumor effect in vitro and in vivo.
Need to check novelty before this filing date? Find Prior Art